Brisbane, Australia, 6 April 2020 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce the appointment of Dr Michael Stein as a Non-Executive Director, effective immediately.
Michael is currently acting CEO of immuno-oncology company, Valo Therapeutics. Immediately prior to Valo, Michael was the founding CEO of OxStem Ltd, an award-winning biotechnology spin-out from the University of Oxford. Michael previously served as founding CEO for Doctor Care Anywhere, a UK-based telemedicine platform acquired by Synergix in 2015. In 2001, he co-founded the Map of Medicine with University College London and was founding CEO. The Map was a set of clinical algorithms that represented the patient healthcare journey from suspected diagnosis to treatment across all healthcare settings. The Map was nationally licensed across NHS England and was acquired by Hearst Business Media in 2008.
Michael graduated as a medical doctor and biochemist from the University of Cape Town and with a doctorate in Physiological Sciences from the University of Oxford, which he attended as a Rhodes Scholar.
ResApp Chairman, Dr Roger Aston said, “We are excited to have Michael join the ResApp board of directors. Michael is a highly experienced serial entrepreneur who has a deep experience of business operations and strategic development across a range of healthcare enterprises. In particular, his experience in UK-based telehealth and partnering with the NHS will be invaluable as ResApp expands its footprint into Europe.”
“ResApp’s technology is ground-breaking and will greatly enhance the patient journey across a wide range of respiratory diseases, including sleep apnoea,” added Dr Michael Stein. “I am honoured to work with the ResApp team to help improve clinical outcomes through faster and more accurate diagnosis for millions of patients across the world.”
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp’s clinically-validated products include ResAppDx-EU, a CE marked and TGA approved smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a CE marked and soon-to-be ARTG listed at-home sleep apnoea screening app for consumers to self-assess their risk of sleep apnoea. For more information, visit www.resapphealth.com.au.
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2021 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257, South Korean Patent No. 1020812410000 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.